Skip to main content
OpenTrials

Clinical trial condition

HER2-negative Breast Cancer

Explore clinical trials studying HER2-negative Breast Cancer. Study availability and eligibility vary by location and protocol.

109 public trials 55 recruiting studies
Refine in advanced search Browse all conditions

HER2-negative Breast Cancer trial results

Recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

NCT06382948

Conditions
Advanced Breast Cancer, ER-positive Breast Cancer, ESR1 Gene Mutation, +1 more
Locations
  • Medizinische Universität Innsbruck Innsbruck, Austria
  • Ordensklinikum Linz Barmherzige Schwestern Linz, Austria
  • Ordination Priv.-Doz. Dr. Michael Hubalek Schwaz, Austria
  • Medical University of Vienna Vienna, Austria
View all 104 locations
View Trial Details
Recruiting

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

NCT06993506

Conditions
Disease Attributes, HER2-negative Breast Cancer, Metastasis, +6 more
Locations
  • Cancer Hospital, Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China
  • The Second Affiliated Hospital of Anhui Medical University Hefei, Anhui, China
  • Peking University First Hospital Beijing, Beijing Municipality, China
  • Chinese PLA General Hospital Beijing, Beijing Municipality, China
View all 19 locations
View Trial Details
Recruiting

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

NCT07281833

Conditions
Advanced Breast Cancer, Breast Cancer, Breast Diseases, +14 more
Locations
  • Institut Jules Bordet Anderlecht, Belgium
  • St. Elisabeth-Krankenhaus GmbH, Brustzentrum - Senologie Cologne, North Rhine-Westphalia, Germany
  • Universitätsklinikum Essen Essen, North Rhine-Westphalia, Germany
  • Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus Mönchengladbach, North Rhine-Westphalia, Germany
View all 16 locations
View Trial Details
Recruiting

Sacituzumab Govitecan In TNBC

NCT04230109

Conditions
Breast Diseases, Breast Neoplasms, ER-negative Breast Cancer, +9 more
Locations
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Massachusetts General Hospital - North Shore Cancer Center Danvers, Massachusetts, United States
View Trial Details
Recruiting

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

NCT05467891

Conditions
HER2-negative Breast Cancer, Hormone Receptor-Positive Breast Cancer, Locoregional Recurrence
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of Arizona Phoenix, Arizona, United States
  • Georgetown University Washington D.C., District of Columbia, United States
  • Orlando Health Cancer Institute Orlando, Florida, United States
View all 21 locations
View Trial Details

Related conditions